ETRA

Electra Therapeutics, Inc. is a clinical-stage biotechnology company. It develops therapies that target signal regulatory proteins for the treatment of novel targets for diseases in immunology and cancer. Its product, ELA026, is a monoclonal antibody that targets signal regulatory protein on the cell surface of myeloid and T cells and depletes pathological immune cells, enabling medical professionals to find an approved treatment for secondary hemophagocytic lymphohistiocytosis, a life-threatening hyperinflammatory condition. The company was incorporated in 2018 and is based in South San Francisco, California.